eligibility_summary
Eligible: must be benefiting and eligible per parent study to continue Roche IMP or comparator (no commercial access), able to comply, and start within 7 days of the allowed treatment gap. Exclude: met parent-study discontinuation criteria, drug/comparator commercially available and accessible, other anti-cancer therapy in gap, permanently stopped study drugs, unresolved SAEs (>Grade 1 or above baseline), or enrolled in another therapeutic trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05862285 is an open-label rollover study providing continued access to Roche agents as mono- or combo-therapy in cancer. Interventions and mechanisms: Ipatasertib—oral AKT inhibitor (PI3K/AKT signaling) blocking tumor cell survival/proliferation, Inavolisib—oral PI3Kα-selective inhibitor, targeting PIK3CA-driven tumors, Entrectinib—oral TKI against NTRK1/2/3, ROS1, ALK fusion kinases, Atezolizumab—anti–PD-L1 monoclonal antibody restoring antitumor T-cell activity, Tiragolumab—anti–TIGIT mAb boosting T/NK-cell responses, Bevacizumab—anti–VEGF-A mAb inhibiting angiogenesis, plus fixed-dose tiragolumab+atezolizumab. Targeted cells/pathways: tumor cells with PI3K/AKT pathway or TRK/ROS1/ALK fusions, PD-L1+ tumor/myeloid cells, TIGIT+ T/NK cells (via CD155 axis), endothelial VEGF signaling and tumor vasculature.